NASDAQ:LIMN

Liminatus Pharma Q2 2025 Earnings Results & Report

Liminatus Pharma logo
$2.51 -0.30 (-10.68%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$2.68 +0.17 (+6.77%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Liminatus Pharma reported Q2 2025 earnings on October 4, 2025. The company reported EPS of -$2.50.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
After Market Closes

Liminatus Pharma EPS Results

Actual EPS
-$2.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Liminatus Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Liminatus Pharma Q2 2025 Earnings FAQ

Liminatus Pharma (NASDAQ:LIMN) reported earnings of -$2.50 per share for Q2 2025. The report was announced on Saturday, October 4, 2025.

Liminatus Pharma Earnings Headlines

Liminatus Pharma (NASDAQ:LIMN) Stock Jumps 7.9% - Still a Buy?
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
Liminatus Pharma regains NASDAQ compliance
See More Liminatus Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Liminatus Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Liminatus Pharma and other key companies, straight to your email.

About Liminatus Pharma

Liminatus Pharma (NASDAQ:LIMN) is a biopharmaceutical company focused on developing immunotherapies for cancer. Its research centers on targets in the tumor microenvironment that can interfere with the body’s immune response to cancer.

The company’s lead program, LMP-001, is an antibody designed to target Galectin-9, an immune-regulating protein associated with tumor growth and immune suppression. Liminatus is also advancing a pipeline of cancer therapies based on its immuno-oncology research.

The company’s work is focused on drug development rather than marketed products, and its programs are intended for potential use across cancer types. Publicly available information about its geographic reach and leadership is limited.

View Liminatus Pharma Profile